From production to patent: The CureVac way
All of our mRNA-based active ingredients for various fields of application originate from a common technology platform and are based on identical source materials. This enables CureVac to produce all mRNA using a universal process—even at a Good Manufacturing Practice (GMP) level of quality. CureVac is truly a one-stop shop for mRNA therapeutics, encompassing every step along the R&D journey, from discovery to production. Our high standards for discovery and production have led to high returns—we currently have over 700 granted patents, with almost 500 additional patent applications pending for approval.
mRNA production, inspired by programming
At CureVac, we describe our production philosophy as “biopharma meets IT.” Much like a programmer will write a code that carries instructions to a computer, during our R&D process, we use mRNA sequences to “write” a new “code” that will be translated by the body to the corresponding protein. This process means we have the possibility to use the same, standardized process to produce all of our mRNA therapeutics.
Where the science happens
CureVac has developed the entire, end-to-end manufacturing process itself and has extensive intellectual property covering its production techniques and technologies. We manufacture our mRNA therapeutics in our own GMP-compliant plants, which are 100% dedicated to producing high-quality mRNA molecules for biomedicine—including the world’s first. Our production plants are:
Our GMP-compliant facilities
Technology Park Tübingen—Reutingen Gmbh©.
Meet The RNA PrinterTM: our mobile production facility
No longer will mRNA therapeutic production be limited by large facility production. We are continuing to develop a portable mRNA “printing” facility – we call it The RNA Printer™. Producing ≥1g of product every two weeks, The RNA Printer™ assists with a rapid response to outbreaks and can be stationed in hospitals to provide personalized medicine.
